Since 2017, the Food and Drug Administration (FDA) has approved the use of three different agents for tumor-agnostic treatment: pembrolizumab (for patients with microsatellite instability or high tumor mutational burden) and larotrectinib and entrectinib (both for use in patients harboring tumors ...
Consequently, the utilization of ICT in healthcare systems has been on the rise worldwide [1]. E-health, which refers to the application of ICT in healthcare provision, is crucial for strengthening the healthcare system [2]. One specific ICT solution is the EHR system, designed to capture...